CN1742724A - Dehydro eleagnine derivative, its synthesizing method and use - Google Patents
Dehydro eleagnine derivative, its synthesizing method and use Download PDFInfo
- Publication number
- CN1742724A CN1742724A CN 200410074203 CN200410074203A CN1742724A CN 1742724 A CN1742724 A CN 1742724A CN 200410074203 CN200410074203 CN 200410074203 CN 200410074203 A CN200410074203 A CN 200410074203A CN 1742724 A CN1742724 A CN 1742724A
- Authority
- CN
- China
- Prior art keywords
- eleagnine
- dehydro
- residue
- acid
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LPIJOZBIVDCQTE-UHFFFAOYSA-N tetrahydroharman Chemical class N1C2=CC=CC=C2C2=C1C(C)NCC2 LPIJOZBIVDCQTE-UHFFFAOYSA-N 0.000 title claims description 28
- 238000000034 method Methods 0.000 title abstract description 4
- 230000002194 synthesizing effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 22
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 10
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000001387 anti-histamine Effects 0.000 claims abstract description 7
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 7
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims abstract description 7
- 230000004648 relaxation of smooth muscle Effects 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 19
- -1 amino ethylamino Chemical group 0.000 claims description 14
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 claims description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- 238000010189 synthetic method Methods 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 4
- 238000007127 saponification reaction Methods 0.000 claims description 4
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 3
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims description 3
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims description 3
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 3
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 239000012286 potassium permanganate Substances 0.000 claims description 3
- 238000007171 acid catalysis Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 18
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 210000003405 ileum Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000005899 aromatization reaction Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000006356 dehydrogenation reaction Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PNZVFASWDSMJER-UHFFFAOYSA-N acetic acid;lead Chemical compound [Pb].CC(O)=O PNZVFASWDSMJER-UHFFFAOYSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a dehydroeleagnine derivative, its synthesizing method and application. The invented compound is prepared by making side chain carboxylic group of dehydroeleagnine be connected with diazanyl, aminoethylamino-group, dehydroeleagnine-3-formaminoethylamino-group or amino-acid residue. The invented compound has stronger smooth muscle relaxation activity and antihistamine activity.
Description
Technical field
The present invention relates to alcaloid-derivatives, relate in particular to the new dehydro eleagnine derivative of a class, its preparation method and application thereof.
Background technology
The leaf energy antiasthmatic-antitussive of climing Fructus Elaeagni and corner piece Fructus Elaeagni, fruit energy astringing to arrest diarrhea, root can stop blooding.Main effective ingredient in climing Fructus Elaeagni and the corner piece Fructus Elaeagni is eleagnine (Lin Qishou, medicinal herb components chemistry, Science Press, 1977,768).The chemical structural formula of eleagnine is as follows:
Eleagnine
The inventor notices, after this Alkaloid dehydrogenation aromatisation or retentive activity or enhanced activity, kept anti-tumor activity by (obtaining yageine) after the banisterine dehydrogenation after for example.The inventor is also noted that the water-soluble degree of this Alkaloid is all low, and bioavailability is all poor.Also there is same problem in eleagnine.In order to overcome these problems, the present invention introduces diazanyl then with eleagnine dehydrogenation aromatisation, amino ethylamino, and amino acid residue provides a series of dehydro eleagnine derivatives.
Summary of the invention
Technical problem to be solved by this invention is with eleagnine dehydrogenation aromatisation, introduces diazanyl then, amino ethylamino, and amino acid residue provides a series of dehydro eleagnine derivatives to overcome the defective of above-mentioned eleagnine.
Technical problem to be solved by this invention realizes by following approach:
A kind of dehydro eleagnine derivative has the structure of following general formula I,
General formula I
Wherein R is diazanyl, amino ethylamino, dehydro eleagnine-3-formamido group ethylamino or amino acid residue.
In the above-mentioned general formula compound, wherein said L-amino acid residue is glycine residue, L-alanine residue, L-valine residue, L-threonine residues, L-phenylalanine residue, L-tyrosine residue, L-leucine residue, L-isoleucine residue, L-proline residue, L-glutaminic acid residue or L-serine residue.
Another technical problem to be solved by this invention provides the synthetic method of above-mentioned general formula compound.
The synthetic method of dehydro eleagnine derivative of the present invention may further comprise the steps:
1) reaction of L-tryptophan and acetaldehyde generates the 1-methyl isophthalic acid under acid catalysis, and 2,3,4-tetrahydrochysene-B-carboline-3-carboxylic acid,
2) with the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylic acid and SOCl
2, methanol reaction generates the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester,
3) with the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester oxidation generates yageine-3-carboxylate methyl ester,
4) dehydro eleagnine-3-carboxylate methyl ester saponification is generated dehydro eleagnine-3-carboxylic acid, then be translated into the active ester of dehydro eleagnine-3-carboxylic acid, active ester and the aminoacid reaction with dehydro eleagnine-3-carboxylic acid at last promptly gets general formula compound of the present invention.
In the above-mentioned synthetic method, wherein the used acid of catalysis L-tryptophan and acetaldehyde reaction is mineral acid in the step 1), is preferably 98% sulphuric acid; Used oxidant is KMnO4 in the step 3); Alkali in the step 4) that dehydro eleagnine-3-carboxylate methyl ester saponification is used is strong inorganic base, is preferably NaOH; Wherein the active ester of the yageine-3-carboxylic acid that reacts with L-aminoacid in the step 4) is the commonly used active ester during polypeptide synthesizes, and for example paranitrophenol ester, N-BTA ester and N-hydroxy-succinamide ester are preferably the N-hydroxy-succinamide ester; Amino acid residue described in the step 4) is glycine residue, L-alanine residue, L-valine residue, L-threonine residues, L-phenylalanine residue, L-tyrosine residue, L-leucine residue, L-isoleucine residue, L-proline residue, L-glutaminic acid residue or L-serine residue.
The pharmacophore of dehydro eleagnine is a B-carboline, the flexible side-chains connection is introduced in the 3-position of B-carboline can reduce the toxicity enhanced activity, and the indole alkaloid of aromatisation is introduced aminoacid can strengthen its biological activity.The present invention introduces aminoacid in the 3-position of dehydro eleagnine can significantly improve its dissolubility, can strengthen dehydro eleagnine absorption in vivo and transhipment accordingly, thereby can significantly improve its anti-histamine activity and smooth muscle relaxation activity.
Description of drawings
The synthetic route chart of Fig. 1 The compounds of this invention, wherein AA is an amino acid residue;
The specific embodiment
Specify the present invention below with reference to embodiment, embodiments of the invention only are used to technical scheme of the present invention is described, and non-limiting essence of the present invention.
The preparation of The compounds of this invention intermediate
One, 1-methyl isophthalic acid, 2,3, the preparation of 4-tetrahydrochysene-B-carboline-3-carboxylic acid
Stir down 2.0g L-tryptophan is mixed with 0.2ml98% sulphuric acid and 20ml water, in solution, add 2ml40% acetaldehyde then, behind the room temperature reaction 6h, have colorless solid to separate out, use NaHCO
3Neutralization reaction solution leaves standstill 1h to PH6-7, sucking filtration, and dry 2.2g (95%) title compound that gets is colorless solid, mp286-288 ℃.
Two, 1-methyl isophthalic acid, 2,3, the preparation of 4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester
Cryosel is bathed down and slowly drip 1mlSOCl in 10ml methanol
2, remove ice bath behind the reaction 15min, in solution, add the 2gl-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylic acid, room temperature reaction spends the night.Have faint yellow solid to separate out, to PH7, leave standstill sucking filtration behind the 15min with 10% sodium carbonate neutralization reaction mixture, 2g (94%) title compound, be the oyster solid.
Three, the preparation of dehydro eleagnine-3-carboxylate methyl ester (1)
(A) 5g (20mmol) 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester is dissolved in 50ml DMF.Cryosel is bathed and is stirred gradation down and reacts a large amount of heat releases toward interior adding 4.5g (28mmol) KMnO4.Reaction 1h recession deicing is bathed, and room temperature reaction spends the night.The reactant mixture sucking filtration, filtrate chamber's relaxing the bowels with purgatives of warm nature dries up, the light yellow solid that obtains soaks with methanol, leach black residue, filtrate decompression is concentrated into dried, and the yellow solid that obtains merges with the black residue that leaches and uses recrystallizing methanol, gets shallow 3.2g (65%) title compound, be yellow solid, mp.243-244 ℃.FAB-MS：m/e?241[M+H]
+。
(B) with 2.5g (10mmol) 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester, 0.7g (20mmol) sulfur powder and 20ml anhydrous dimethyl benzene mix and refluxed 4 days.Have a large amount of hydrogen sulfide gas to emit in the reaction, the bottle wall has red crystals to separate out.Stopped reaction places refrigerator overnight with reactant liquor, and filter next day.Filtering residue is washed with the 7ml cold xylene earlier, washes with petroleum ether then, gets 1.6g (67%) title compound, is coffee-like solid, 242 ℃ of mp.
(C) psychrolusia and in stir fast down toward 0.5g (2.1mmol) 1-methyl isophthalic acid, 2,3, add 2.25g (5.1mmol) in 4-tetrahydro-b-carboline-3-carboxylate methyl ester and the 10ml glacial acetic acid, lead tetra-acetate.Reactant mixture stirs 15min, adds 0.5g (5.1mmol) oxalic acid, restir 1h, the precipitation of collecting off-white color.The precipitation of collecting is washed with small amount of methanol, is suspended in then in 75ml water and chloroform (1: the 2 v/v) mixed solution.Suspension neutralizes with sodium bicarbonate, filters.Filtering residue is washed with minimum of chloroform, and merging filtrate is told chloroform layer.(3 * 10ml), the chloroform layer of merging spends the night with anhydrous sodium sulfate drying water layer, filters, and filtrate decompression is concentrated into dried, gets 0.25g (50%) title compound, is yellow solid, 242 ℃ of mp with chloroform extraction.
Four, the preparation of dehydro eleagnine-3-carboxylic acid (2)
5g1-methyl-B-carboline-3-carboxylate methyl ester is dissolved in 120ml 2N NaOH, be heated to 60 ℃ of reaction 4h, solid dissolves gradually, and solution becomes clarification, cessation reaction, put and be chilled to room temperature, be neutralized to neutrality, have a large amount of yellow solids to separate out with concentrated hydrochloric acid, standing over night in the refrigerator, sucking filtration gets 3.86g (82%) title compound, is yellow solid, mp292 ℃.FAB-MS(m/e)241[M+H]
+。
The preparation of embodiment 1 N-dehydro eleagnine-3-formylglycine (6a)
240mg (1.0mmol) dehydro eleagnine-3-carboxylic acid is dissolved in the 15ml anhydrous tetrahydro furan, cryosel is bathed and is stirred and adds 116mg (1.0mmol) N-hydroxy-succinamide and 200mg (1.0mmol) DCC down, reactant mixture reacts 2h under ice bath, room temperature reaction 24h.When TLC detected no raw material, reactant mixture filtered, adds 75mg (1.0mmol) glycine in filtrate.Reactant mixture stirring at room 40h, TLC (CHCl
3: CH
3OH=10: 1) show that glycine disappears.Reactant mixture is evaporated to dried.Purification by silica gel column chromatography is washed, used to residue with ether, obtains 226mg (80%) title compound, is colorless solid.Mp170-171℃，FAB-MS(m/e)284[M+H]
+IR(KBr)3434，3363，3232，3087，2960，1660，1604，1580，1545，1453，1373cm
-1.
1H-NMR(DMSO-d6)δ＝11.97(s，1H)，8.83(t，J＝8.2Hz，1H)，8.68(s，1H)，8.36(d，J＝7.8Hz，1H)，7.66(d，J＝8.1Hz，1H)，7.59(t，J＝7.5Hz，1H)，7.29(t，J＝7.5Hz，1H)，4.07(d，J＝4.6Hz，2H)，2.88(s，3H).
The preparation of embodiment 2.N-dehydro eleagnine-3-formyl-L-alanine (6b)
With the operation of embodiment 1, obtain 241mg (81%) title compound from 89mg L-alanine, be colorless solid.Mp216-218℃，[α]
D＝+2(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)298[M+H]
+，IR(KBr)3433，3364，3239，3080，2961，1660，1604，1589，1545，1452，1374cm
-1.
1H-NMR(DMSO-d6)δ＝11.98(s，1H)，8.69(d，J＝5.2Hz，1H)，8.68(s，1H)，8.36(d，J＝7.8Hz，1H)，7.65(d，J＝8.1Hz，1H)，7.59(t，J＝7.5Hz，1H)，7.31(t，J＝8.1Hz，1H)，4.53(m，J＝5.1Hz，1H)，2.89(s，3H)，1.47(d，J＝6.9Hz，3H)。
The preparation of embodiment 3.N-dehydro eleagnine-3-formyl-L-valine (6c)
With the operation of embodiment 1, obtain 263mg (81%) title compound from 117mg L-valine, be colorless solid.Mp170-172℃，[α]
D＝+6(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)326[M+H]
+IR(KBr)3433，3359，3230，3087，2965，1660，1603，1580，1547，1455，1370cm
-1.
1H-NMR(DMSO-d6)δ＝11.98(s，1H)，8.69(d，J＝4.9Hz，1H)，8.68(s，1H)，8.36(d，J＝7.8Hz，1H)，7.65(d，J＝8.1Hz，1H)，7.59(t，J＝7.5Hz，1H)，7.31(t，J＝8.1Hz，1H)，4.53(m，J＝5.1Hz，1H)，2.89(s，3H)，1.47(d，J＝6.9Hz，3H，).
The preparation of embodiment 4.N-dehydro eleagnine-3-formyl-L-phenylalanine (6d)
With the operation of embodiment 1, obtain 328mg (88%) title compound from 165mg L-phenylalanine, be colorless solid.Mp168-170℃，[α]
D＝+3(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)374[M+H]
+，IR(KBr)3435，3364，3232，3082，2960，1660，1601，1585，1551，1452，1374，760cm
-1.
1H-NMR(DMSO-d6)δ＝12.12(s，1H)，8.70(s，1H)，8.35(d，J＝8.1Hz，1H)，7.67(d，J＝7.8Hz，1H)，7.62(t，J＝7.5Hz，1H)，7.32(t，J＝7.8Hz，1H)，7.30(t，J＝7.5Hz，1H)，7.28(d，J＝7.6Hz，2H)，7.25(t，J＝7.4Hz，2H)，4.82(t，J＝6.3Hz，1H)，3.25(d，J＝4.9Hz，2H)，2.85(s，3H).
The preparation of embodiment 5.N-dehydro eleagnine-3-formyl-L-threonine (6e)
With the operation of embodiment 1, obtain 245mg (75%) title compound from 119mg L-threonine, be colorless solid.Mp194-195℃，[α]
D＝+6(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)327[M+H]
+.IR(KBr)3433，3358，3239，3080，2960，1665，1604，1580，1547，1452，1376cm
-1.
1H-NMR(DMSO-d6)δ＝11.97(s，1H)，8.90(m，J＝5.2Hz，1H)，8.68(s，1H)，8.38(d，J＝7.8Hz，1H)，7.69(d，J＝8.1Hz，1H)，7.67(t，J＝7.5Hz，1H)，7.34(t，J＝7.5Hz，1H)，4.51(d，J＝5.0Hz，1H)，4.32(m，J＝5.0Hz，1H)，3.16(s，1H)，2.95(s，3H)，1.16(d，J＝6.3Hz，3H).
The preparation of embodiment 6.N-dehydro eleagnine-3-formyl-L-tyrosine (6f)
With the operation of embodiment 1, obtain 293mg (75%) title compound from 181mg L-tyrosine, be colorless solid.Mp268-270℃，[α]
D＝-27(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)390[M+H]
+，IR(KBr)3430，3361，3236，3084，2962，1662，1600，1583，1549，1450，1378，762cm
-1.
1H-NMR(DMSO-d6)δ＝12.16(s，1H)，10.82(s，1H)，8.75(s，1H)，8.63(m，J＝5.2Hz，1H)，8.34(d，J＝7.8Hz，1H)，7.66(d，J＝7.8Hz，1H)，7.58(t，J＝7.5Hz，1H)，7.29(t，J＝7.5Hz，1H)，6.98(d，J＝7.5Hz，2H)，6.61(d，J＝7.5Hz，2H)，4.51(m，J＝5.1Hz，1H)，3.14(d，J＝5.3Hz，2H)，2.82(s，3H).
The preparation of embodiment 7.N-dehydro eleagnine-3-formyl-L-leucine (6g)
With the operation of embodiment 1, obtain 295mg (87%) title compound from 131mg L-leucine, be colorless solid.Mp140-140℃，[α]
D＝+5(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)340[M+H]
+，IR(KBr)3433，3365，3238，3087，2960，1664，1602，1581，1547，1452，1380cm
-1.
1H-NMR(DMSO-d6)δ＝11.99(s，1H)，8.69(s，1H)，8.59(d，J＝8.7Hz，1H)，8.35(d，J＝7.8Hz，1H)，7.66(d，J＝7.8Hz，1H)，7.57(t，J＝7.5Hz，1H)，7.29(t，J＝7.5Hz，1H)，4.60(d，J＝5.1Hz，1H)，2.86(s，3H)，1.79-1.99(m，J＝5.1Hz，2H)，1.17(m，J＝5.2Hz，1H)，0.94(d，J＝6.0Hz，6H).
The preparation of embodiment 8.N-dehydro eleagnine-3-formyl-L-isoleucine (6h)
With the operation of embodiment 1, obtain 244mg (72%) title compound from 131mg L-isoleucine, be colorless solid.Mp131-132℃[α]
D＝+3(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)340[M+H]
+，IR(KBr)3435，3364，3244，3087，2960，1664，1602，1583，1546，1453，1380cm
-1.
1H-NMR(DMSO-d6)δ＝12.02(s，1H)，8.70(s，1H)，8.57(d，J＝8.7Hz，1H)，8.36(d，J＝7.8Hz，1H)，7.66(d，J＝8.1Hz，1H)，7.60(t，J＝7.5Hz，1H)，7.30(t，J＝7.5Hz，1H)，4.53(d，J＝5.1Hz，H)，2.86(s，3H)；2.01(m，J＝5.2Hz，1H)，1.21-1.30(m，J＝5.0Hz，2H)，0.96(d，J＝6.9Hz，3H)，0.84(t，J＝5.3Hz，3H).
The preparation of embodiment 9.N-dehydro eleagnine-3-formyl-L-proline (6i)
With the operation of embodiment 1, obtain 258mg (80%) title compound from 115mg L-proline, be colorless solid.Mp145-147℃，FAB-MS(m/e)324[M+H]
+，IR(KBr)3431，3362，3241，3085，2962，1661，1600，1585，1545，1450，1383cm
-1.
1H-NMR(DMSO-d6)δ＝11.84(s，1H)，8.57(s，1H)，8.43(s，1H)，8.31(d，J＝7.2Hz，1H)，7.63(d，J＝8.1Hz，1H)，7.57(t，J＝7.5Hz，1H)，7.27(t，J＝7.5Hz，1H)，4.49(m，J＝6.2Hz，1H)，3.71(t，J＝6.6Hz，2H)，2.81(s，3H)，2.24(m，J＝6.2Hz，2H)，2.05(t，J＝6.5Hz，2H).
The preparation of embodiment 10.N-dehydro eleagnine-3-formyl-L-glutamic acid (6j)
With the operation of embodiment 1, obtain 266mg (75%) title compound from 147mg L-glutamic acid, be colorless solid.300 ℃ of (decomposition) [α] of Mp
D=+4 (C=0.5, EtOH/DMSO, 4: 1) FAB-MS (m/e) 356[M+H]
+.IR (KBr) 3435,3364,3245,3088,2965,1664,1602,1583,1544,1452,1380cm
-1.
1H-NMR (DMSO-d6) δ=11.99 (s, 1H), 11.87 (s, 1H), 8.73 (s, 1H), 8.30 (d, J=7.8Hz, 1H), 7.60 (d, J=7.8Hz, 1H), 7.55 (t, J=7.5Hz, 1H), 7.27 (t, J=7.2Hz, 1H), 3.30 (m, J=5.8Hz, 1H), 2.79 (s, 3H), 1.90 (t, J=4.5Hz, 2H), 1.13 (m, J=5.5Hz, 2H).
The preparation of embodiment 11.N-dehydro eleagnine-3-formyl-L-aspartic acid (6k)
With the operation of embodiment 1, obtain 273mg (80%) title compound from 133mg L-aspartic acid, be colorless solid.Mp?220-221℃[α]
D＝+5(C＝0.5，EtOH/DMSO，4∶1)，FAB-MS(m/e)342[M+H]
+IR(KBr)3430，3368，3241，3087，2963，1668，1604，1585，1542，1455，1382cm
-1.
1H-NMR(DMSO-d6)δ＝12.02(s，1H)，1189(s，1H)，8.72(s，1H)，8.31(d，J＝7.8Hz，1H)，7.58(d，J＝7.8Hz，1H)，7.55(t，J＝7.5Hz，1H)，7.27(t，J＝7.2Hz，1H)；3.26(m，J＝5.9Hz，1H)，2.81(s，3H)，1.85(d，J＝6.2Hz，2H)。
The preparation of embodiment 12.N-dehydro eleagnine-3-formyl-L-serine (6l)
With the operation of embodiment 1, obtain 250mg (80%) title compound from 105mg L-serine, be colorless solid.Mp168-170 ℃ of (decomposition) [α]
D=+5 (C=0.5, EtOH/DMSO, 4: 1), FAB-MS (m/e) 313[M+H]
+IR (KBr) 3433,3370,3243,3085,2966,1666,1601,1589,1549,1456,1380cm
-1.
1H-NMR (DMSO-d6) δ=12.02 (s, 1H), 8.67 (s, 1H), 8.56 (d, J=8.1Hz, 1H), 8.35 (d, J=7.8Hz, 1H), 7.66 (d, J=7.8Hz, 1H), 7.58 (t, J=7.5Hz, 1H), 7.29 (t, J=7.5Hz, 1H), 4.72 (m, J=5.8Hz, 1H), 3.12 (d, J=5.9Hz, 2H) 2.83 (s, 3H).
The preparation of embodiment 13. dehydro eleagnines-3-formylhydrazine (3)
2.5ml (50.0mmol) N
2H
4.H
2O and 2.0mlCH
3The mixed solution of OH is heated to 80 ℃, in solution, add 480mg (2mmol) B-carboline-3-carboxylate methyl ester that is dissolved in 10ml chloroform and 2ml methanol mixed solution, 2.5h in add, mixture stirring at room to thin layer detects no raw material point, there are a large amount of white solids to separate out, concentrating under reduced pressure removes and desolvates, and residue uses column chromatography (CHCl
3/ MeOH 3: 1, v/v), gets 180mg (38%) title compound, for getting yellow solid, mp.294-295 ℃, FAB-MS (m/e) 241[M+H]
+, 1H-NMR (DMSO-d6) 11.90 (s, 1H), 8.63 (s, 1H), 8.34 (d, J=7.8Hz, 1H), 7.63 (d, J=8.1Hz, 1H, H-5), 7.56 (t, J=7.5Hz, 1H), 7.26 (t, J=7.5Hz, 1H), 4.60 (m, 1H), 2.80 (s, 3H).
The preparation of embodiment 14.3-ethylamino-dehydro eleagnine-3-Methanamide (4)
12ml (180mmol) 1, the 2-ethylenediamine is heated to 85-90 ℃, in solution, add 1g (4.2mmol) B-carboline-3-carboxylate methyl ester that is dissolved in 30ml chloroform and 10ml methanol mixed solution, 2.5h in add, mixture is back to thin layer and detects no raw material point, concentrating under reduced pressure removes and desolvates, and residue uses column chromatography (CHCl
3/ MeOH, 3: 1, v/v), get 797mg (71%) title compound, be yellow solid, mp 172-173 ℃.Obtain the product of 20mg (1.78%) 1 and two molecule 1s-methyl-B-carboline-3-carboxylic acid reaction during column chromatography for separation, i.e. N, N '-two dehydro eleagnines-3-formyl ethylenediamine (5).N, Mp 210-211 ℃ of N '-two dehydro eleagnines-3-formyl ethylenediamine (5), FAB-MS (m/e) 477[M+H]
+, 1H-NMR (DMSO-d6) 11.92 (s, 2H), 8.66 (s, 2H), 8.34 (d, J=7.8Hz, 2H), 7.63 (d, J=8.1Hz, 1H), 7.57 (t, J=7.5Hz, 1H), 7.27 (t, J=7.5Hz, 1H), 3.24-3.42 (m, 4H), 2.80 (s, 6H).
The anti-histamine activity of test example 1 The compounds of this invention
One, test material:
1, for test agent: chemical compound 1,2,3,4,5,6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l that the embodiment of the invention is prepared.
2, laboratory animal: 200-250g Cavia porcellus, male and female are not limit (available from Department Of Medicine, Peking University's laboratory animal portion)
Two, test method and result
The 200-250g Cavia porcellus, male and female are not limit, the head of fiercelying attack is put to death Cavia porcellus, open the abdominal cavity rapidly, take out near the partial ileum of returning blind hole, put into the culture dish that fills tyrode's solution, be divided into the 1.5-2.0cm segment with shears, with the tyrode's solution content of flush away intestinal segment gently, get that wherein two sections are fixed on the brandreth and wholely immerse that (end is fixed in the Magnus' bath, the other end is connected on the tonotransducer), all the other intestinal segments are put into and are filled the triangular flask of using the saturated tyrode's solution of oxygen in advance, and 4 ℃ of preservations (in 24 hours) are standby.Add the 15ml tyrode's solution in the Magnus' bath, contain 5%CO with suitable speed (40 bubbles of per minute bell) feeding
2Oxygen, the water bath with thermostatic control water temperature is controlled at 38 ℃ ± 0.5 ℃, intestinal segment adds the pretension of 0.5-1 gram, incubation was measured after 0.5 hour.
Start monitor, add the solution (being dissolved in 5: 1 mixed solvents of ethanol or ethanol and dimethyl sulfoxide) of one of 15ul blank solvent or each testing sample in the Magnus' bath, be incubated adding (3.5*10 after 5 minutes
-4G/ml) 1.5ul histamine solution (final concentration 3.5*10
-8G/ml), recording curve reaches and stops record after the highest.Clean intestinal segment three times (15ml*3) with the constant temperature tyrode's solution, start monitor, treat to repeat above-mentioned experiment after the baseline stability.Ileum tension force under measuring space blank solvent and the testing sample effect, with the tensile meansigma methods of ileum (being designated as 100%) under the blank solvent effect of adjacent twice mensuration is that benchmark calculates the tensile percent of ileum under the testing sample effect, measure six data points, calculate mean tension percent A, then 1-A is the suppression ratio I of this sample under this concentration, use the SPSS software statistics, the results are shown in Table 1.(add 1.5ul histamine solution and sample solution in the Magnus' bath when measuring anti-histamine activity, add blank solvent and sample solution in the Magnus' bath when measuring " ileum tension force ")
Table 1 chemical compound anti-histamine activity of the present invention
The chemical compound suppression ratio, % P
1 7.7±0.0264 ＜0.05
2 5.7±0.0288 ＜0.05
3 10.7±0.0328 ＜0.05
4 24.8±0.05120 ＜0.01
5 41.3±0.03930 ＜0.01
6a 11.7±0.0388 ＜0.05
6b -19.3±0.1040 ＜0.01
6c -19.3±0.1040 ＜0.01
6d 23.3±0.0634 ＜0.01
6e -15.3±0.0717 ＜0.01
6f -9.00±0.0363 ＞0.05
6g -50.0±0.0657 ＜0.01
6h 3.17±0.2032 ＞0.05
6i 26.3±0.0534 ＜0.01
6j -16.7±0.0814 ＜0.01
6k 36.9±0.0635 ＜0.01
61 -7.50±0.08040 ＞0.05
N=6, the final concentration of chemical compound are 10
-1Mol/l
Result of the test shows that chemical compound of the present invention has very high anti-histamine activity.
Test example 2 The compounds of this invention ileum diastole activity
One, test material:
1, for test agent: chemical compound 1,2,3,4,5,6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l that the embodiment of the invention is prepared.
2, laboratory animal: 200-250g Cavia porcellus, male and female are not limit (available from Department Of Medicine, Peking University's laboratory animal portion)
Two, test method and result
The 200-250g Cavia porcellus, male and female are not limit, the head of fiercelying attack is put to death Cavia porcellus, open the abdominal cavity rapidly, take out near the partial ileum of returning blind hole, put into the culture dish that fills tyrode's solution, be divided into the 1.5-2.0cm segment with shears, with the tyrode's solution content of flush away intestinal segment gently, getting wherein two sections is fixed on special shelf and (goes up and wholely immerse that (end is fixed in the Magnus' bath, the other end is connected on the tonotransducer), all the other intestinal segments are put into and are filled the triangular flask of using the saturated tyrode's solution of oxygen in advance, and 4 ℃ of preservations (in 24 hours) are standby.Add the 15ml tyrode's solution in the Magnus' bath, contain 5%CO with suitable speed (40 bubbles of per minute bell) feeding
2Oxygen, Huan's tepidarium water temperature is controlled at 38 ℃ ± 0.5 ℃, intestinal segment adds the pretension of 0.5-1 gram, incubation was measured after 1 hour.
Start monitor, add one of 15ul blank solvent or each testing sample solution (testing sample is dissolved in ethanol or ethanol and 5: 1 mixed solvents of dimethyl sulfoxide) in the Magnus' bath, be incubated 5 minutes and make baseline stability.Ileum tension force under measuring space blank solvent and the testing sample effect, with the tensile meansigma methods of ileum under the blank solvent effect of adjacent twice mensuration is that benchmark calculates the tensile percent of ileum under the testing sample effect, measure six data points, calculate average diastole tension force percent B.The percent of diastole ileum and theoretical value 0 (diastolic rate of non-activity chemical compound and suppression ratio are 0) are done one-way ANOVA significance test, the results are shown in Table 2.
Table 2. chemical compound diastole of the present invention ileum activity
Chemical compound diastolic rate % P
1 21.0±4.07 ＜0.01
2 11.5±5.07 ＜0.01
3 41.0±6.07 ＜0.01
4 51.0±7.07 ＜0.01
5 57.3±1.75 ＜0.01
6a 0.83±2.04 ＞0.05
6b 24.0±4.82 ＜0.01
6c 32.8±6.82 ＜0.01
6d 17.8±3.06 ＜0.01
6e 27.5±6.35 ＜0.01
6f 15.2±4.07 ＜0.01
6g 68.2±4.35 ＜0.01
6h 17.5±9.48 ＜0.01
6i 66.2±3.35 ＜0.01
6j 37.5±9.52 ＜0.01
6k 70.5±3.44 ＜0.01
6l 17.8±5.23 ＜0.01
N=6, final concentration are 10
-1Mol/l
Result of the test shows that chemical compound of the present invention has stronger smooth muscle relaxation activity.
Claims (10)
1, class dehydro eleagnine-3-formyl amino acid formyl amino acid, hydrazides or amide derivatives have the structure of following general formula I:
General formula I
Wherein R is diazanyl, amino ethylamino, dehydro eleagnine-3-formamido group ethylamino or amino acid residue.
2, according to the described dehydro eleagnine derivative of claim 1, wherein said amino acid residue is glycine residue, L-alanine residue, L-valine residue, L-threonine residues, L-phenylalanine residue, L-tyrosine residue, L-leucine residue, L-isoleucine residue, L-proline residue, L-glutaminic acid residue or L-serine residue.
3, the synthetic method of compound of Formula I, the definition of this general formula may further comprise the steps according to claim 1:
1) reaction of L-tryptophan and acetaldehyde generates the 1-methyl isophthalic acid under acid catalysis, and 2,3,4-tetrahydrochysene-B-carboline-3-carboxylic acid,
2) with the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylic acid and SOCl
2, methanol reaction generates the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester,
3) with the 1-methyl isophthalic acid, 2,3,4-tetrahydrochysene-B-carboline-3-carboxylate methyl ester oxidation generates removes dehydro eleagnine-3-carboxylate methyl ester,
4) dehydro eleagnine-3-carboxylate methyl ester saponification is generated dehydro eleagnine-3-carboxylic acid, then be translated into the active ester of dehydro eleagnine-3-carboxylic acid, active ester and the aminoacid reaction with dehydro eleagnine-3-carboxylic acid at last promptly gets general formula compound of the present invention.
4, according to the described synthetic method of claim 3, the used acid of catalysis L-tryptophan and acetaldehyde reaction is mineral acid in the step 1).
5, according to the described synthetic method of claim 3, wherein used oxidant is KMnO4 in the step 3).
6, according to the described synthetic method of claim 3, wherein the alkali that dehydro eleagnine-3-carboxylate methyl ester saponification is used is strong inorganic base in the step 4).
7, according to the described synthetic method of claim 3, wherein the active ester of the dehydro eleagnine-3-carboxylic acid that reacts with L-aminoacid in the step 4) is the paranitrophenol ester, N-BTA ester or N-hydroxy-succinamide ester.
8, the purposes of compound of Formula I in preparation histamine receptor antagonists medicine.
General formula I
Wherein R is diazanyl, amino ethylamino, dehydro eleagnine-3-formamido group ethylamino or amino acid residue.
9, the purposes of compound of Formula I in preparation smooth muscle relaxation agent medicine.
General formula I
Wherein R is diazanyl, amino ethylamino, dehydro eleagnine-3-formamido group ethylamino or amino acid residue.
10, a kind of have anti-histamine activity or an active pharmaceutical composition of diastole smooth muscle, contains the compound of Formula I and the pharmaceutically acceptable carrier of the described structure of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100742031A CN100360129C (en) | 2004-09-03 | 2004-09-03 | Dehydro eleagnine derivative, its synthesizing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100742031A CN100360129C (en) | 2004-09-03 | 2004-09-03 | Dehydro eleagnine derivative, its synthesizing method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1742724A true CN1742724A (en) | 2006-03-08 |
| CN100360129C CN100360129C (en) | 2008-01-09 |
Family
ID=36138350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100742031A Expired - Fee Related CN100360129C (en) | 2004-09-03 | 2004-09-03 | Dehydro eleagnine derivative, its synthesizing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100360129C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104177376A (en) * | 2013-05-20 | 2014-12-03 | 新疆华世丹药物研究有限责任公司 | 1-Position diamine beta-carboline alkali compound, and preparation method, medicinal composition and use thereof |
| CN104177377A (en) * | 2013-05-20 | 2014-12-03 | 新疆华世丹药物研究有限责任公司 | 3-Position diamine beta-carboline alkali compound, and preparation method, medicinal composition and use thereof |
| CN104744494A (en) * | 2013-12-27 | 2015-07-01 | 新疆华世丹药物研究有限责任公司 | 7 site-connected bis(beta-carboline alkaloid) compound and its preparation method, pharmaceutical composition and use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69710182T2 (en) * | 1996-04-04 | 2002-08-29 | F. Hoffmann-La Roche Ag, Basel | USE OF TETRAHYDROBETACARBOLIN DERIVATIVES FOR PREVENTING METASTASIS |
| CN1169809C (en) * | 2001-12-20 | 2004-10-06 | 浙江医药股份有限公司新昌制药厂 | Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application |
-
2004
- 2004-09-03 CN CNB2004100742031A patent/CN100360129C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104177376A (en) * | 2013-05-20 | 2014-12-03 | 新疆华世丹药物研究有限责任公司 | 1-Position diamine beta-carboline alkali compound, and preparation method, medicinal composition and use thereof |
| CN104177377A (en) * | 2013-05-20 | 2014-12-03 | 新疆华世丹药物研究有限责任公司 | 3-Position diamine beta-carboline alkali compound, and preparation method, medicinal composition and use thereof |
| CN104744494A (en) * | 2013-12-27 | 2015-07-01 | 新疆华世丹药物研究有限责任公司 | 7 site-connected bis(beta-carboline alkaloid) compound and its preparation method, pharmaceutical composition and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100360129C (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1069901C (en) | N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same | |
| CN1095841C (en) | Chemical compounds | |
| CN1026322C (en) | Benzoxazole derivative and processes for preparing same | |
| CN1922140A (en) | Method for producing monatin | |
| CN1182434A (en) | Novel peptide derivatives | |
| CN1129216A (en) | Hydroxamic acid derivatives with tricylic substitution | |
| CN1081187C (en) | Inhibitors of prenyl transferases | |
| CN1743326A (en) | Carboline carboxylate derivative, and its synthesizing method and use | |
| CN1558906A (en) | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | |
| CN1028528C (en) | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl) pyrazolo [1,5-a]-1,3,5-triazines | |
| CN1059517A (en) | Acetamide derivative | |
| CN1082370C (en) | Pharmaceutical composition containing 4-oxo-butynic acid | |
| CN1184209C (en) | Chuanxiong alkoxide derivative and its preparation and medicinal composition containing it and use thereof | |
| CN1742724A (en) | Dehydro eleagnine derivative, its synthesizing method and use | |
| CN100494196C (en) | Indole alkaloid derivative, and its preparing method and use | |
| CN1197864C (en) | Process for preparation of pyrazolo pyridazine derivatives | |
| CN1724519A (en) | Indole kind compound with insuline sensitizing activity and its preparation method and use | |
| CN1633421A (en) | Oxazole/thiazol-derivatives activators of the hppar-alpha receptor | |
| CN1131153A (en) | 1-oxy-2-(phenylsulfonamido-) amyl piperidine derivant, its preparation method and medicinal use thereof | |
| CN1810791A (en) | Synthesis process of medicine for treating hemopathy | |
| CN1305486A (en) | Novel compounds derived from alpha-D-xylose, preparation method and therapeutic use | |
| CN1037179C (en) | 1,4-benzoxazino derivatives | |
| CN1636997A (en) | Substituted tricyclocoumarin compound and its prepn and anti-HIV application | |
| CN1065454A (en) | Activity optically active carboxylic acid and method for making thereof and medicinal compositions | |
| CN1156448C (en) | Optical isomer of 3-methyl fentanyl, derivant, synthesizing and its analgesic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080109 Termination date: 20140903 |
|
| EXPY | Termination of patent right or utility model |